Disease modeling of cardiac arrhythmias using human induced pluripotent stem cells

References

• Jervell A, Lange-Nielsen F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957;54:59–68.
   PubMed Web of Science ®Google Scholar
• Krahn AD, Healey JS, Chauhan V, et al. Systematic assessment of patients with unexplained cardiac arrest: cardiac arrest survivors with preserved ejection fraction registry (CASPER). Circulation. 2009;120:278–285.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Maragna R, Vacanti G, et al. Interplay between genetic substrate, QTc duration, and arrhythmia risk in patients with long QT syndrome. J Am Coll Cardiol. 2018;71:1663–1671.
   PubMed Web of Science ®Google Scholar
• Wilde AA, Bezzina CR. Genetics of cardiac arrhythmias. Heart. 2005;91:1352–1358. Epub 2005 Sep 16.
   PubMed Web of Science ®Google Scholar
• Giudicessi JR, Ackerman MJ. Genotype- and phenotype-guided management of congenital long QT syndrome. Curr Probl Cardiol. 2013;38:417–455. Epub 2013 Oct 8.
   PubMed Web of Science ®Google Scholar
• Kawakami H, Aiba T, Yamada T, et al. Variable phenotype expression with a frameshift mutation of the cardiac sodium channel gene SCN5A. J Arrhythm. 2013;29:291–295.
   Google Scholar
• Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci U S A. 1998;95:13726–13731.
   PubMed Web of Science ®Google Scholar
• Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282:1145–1147.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
   PubMed Web of Science ®Google Scholar
• Schlaeger TM, Daheron L, Brickler TR, et al. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015;33:58–63.
   PubMed Web of Science ®Google Scholar
• Yoo SJ, Yoon BS, Kim JM, et al. Efficient culture system for human embryonic stem cells using autologous human embryonic stem cell-derived feeder cells. Exp Mol Med. 2005;37:399–407.
   PubMed Web of Science ®Google Scholar
• Richards M, Fong CY, Chan WK, et al. Human feeders support prolonged undifferentiated growth of human inner cell masses and embryonic stem cells. Nat Biotechnol. 2002;20:933–936.
   PubMed Web of Science ®Google Scholar
• Yue XS, Fujishiro M, Nishioka C, et al. Feeder cells support the culture of induced pluripotent stem cells even after chemical fixation. PLoS One. 2012;7:e32707.
   PubMed Web of Science ®Google Scholar
• Li Y, Powell S, Brunette E, et al. Expansion of human embryonic stem cells in defined serum-free medium devoid of animal-derived products. Biotechnol Bioeng. 2005;91:688–698.
   PubMed Web of Science ®Google Scholar
• Frank S, Zhang M, Scholer HR, et al. Small molecule-assisted, line-independent maintenance of human pluripotent stem cells in defined conditions. PLoS One. 2012;7:e41958.
   PubMed Web of Science ®Google Scholar
• Xu C, Inokuma MS, Denham J, et al. Feeder-free growth of undifferentiated human embryonic stem cells. Nat Biotechnol. 2001;19:971.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30–e41. Epub 2009 Feb 14.
   PubMed Web of Science ®Google Scholar
• Ma J, Guo L, Fiene SJ, et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol. 2011;301:H2006–H2017.
   PubMed Web of Science ®Google Scholar
• Mummery CL, Zhang J, Ng ES, et al. Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res. 2012;111:344–358.
   PubMed Web of Science ®Google Scholar
• Maltsev VA, Rohwedel J, Hescheler J, et al. Embryonic stem cells differentiate in vitro into cardiomyocytes representing sinusnodal, atrial and ventricular cell types. Mech Dev. 1993;44:41–50.
   PubMed Web of Science ®Google Scholar
• Kattman SJ, Witty AD, Gagliardi M, et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell. 2011;8:228–240.
   PubMed Web of Science ®Google Scholar
• Zhang J, Klos M, Wilson GF, et al. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res. 2012;111:1125–1136.
   PubMed Web of Science ®Google Scholar
• Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature. 2008;453:524–528. Epub 2008 Apr 25.
   PubMed Web of Science ®Google Scholar
• Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109:E1848–E1857.
   PubMed Web of Science ®Google Scholar
• Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods. 2014;11:855–860.
   PubMed Web of Science ®Google Scholar
• Lian X, Bao X, Zilberter M, et al. Chemically defined, albumin-free human cardiomyocyte generation. Nat Methods. 2015;12:595–596. Epub 2015 Jul 1.
   PubMed Web of Science ®Google Scholar
• Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014;114:511–523. Epub 2014 Feb 1.
   PubMed Web of Science ®Google Scholar
• Sartiani L, Bettiol E, Stillitano F, et al. Developmental changes in cardiomyocytes differentiated from human embryonic stem cells: a molecular and electrophysiological approach. Stem Cells. 2007;25:1136–1144. Epub 2007 Jan 27.
   PubMed Web of Science ®Google Scholar
• Kadota S, Minami I, Morone N, et al. Development of a reentrant arrhythmia model in human pluripotent stem cell-derived cardiac cell sheets. Eur Heart J. 2013;34:1147–1156. Epub 2012 Dec 4.
   PubMed Web of Science ®Google Scholar
• Lundy SD, Zhu WZ, Regnier M, et al. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev. 2013;22:1991–2002. Epub 2013 Mar 7.
   PubMed Web of Science ®Google Scholar
• Nunes SS, Miklas JW, Liu J, et al. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes. Nat Methods. 2013;10:781–787. Epub 2013 Jun 25.
   PubMed Web of Science ®Google Scholar
• Chan YC, Ting S, Lee YK, et al. Electrical stimulation promotes maturation of cardiomyocytes derived from human embryonic stem cells. J Cardiovasc Transl Res. 2013;6:989–999. Epub 2013 Oct 2.
   PubMed Web of Science ®Google Scholar
• Hirt MN, Boeddinghaus J, Mitchell A, et al. Functional improvement and maturation of rat and human engineered heart tissue by chronic electrical stimulation. J Mol Cell Cardiol. 2014;74:151–161. Epub 2014 May 24.
   PubMed Web of Science ®Google Scholar
• Foldes G, Mioulane M, Wright JS, et al. Modulation of human embryonic stem cell-derived cardiomyocyte growth: a testbed for studying human cardiac hypertrophy? J Mol Cell Cardiol. 2011;50:367–376. Epub 2010 Nov 5.
   PubMed Web of Science ®Google Scholar
• Mihic A, Li J, Miyagi Y, et al. The effect of cyclic stretch on maturation and 3D tissue formation of human embryonic stem cell-derived cardiomyocytes. Biomaterials. 2014;35:2798–2808. Epub 2014 Jan 16.
   PubMed Web of Science ®Google Scholar
• Lee YK, Ng KM, Chan YC, et al. Triiodothyronine promotes cardiac differentiation and maturation of embryonic stem cells via the classical genomic pathway. Mol Endocrinol (Baltimore, Md). 2010;24:1728–1736. Epub 2010 Jul 30.
   PubMedGoogle Scholar
• Yang X, Rodriguez M, Pabon L, et al. Tri-iodo-l-thyronine promotes the maturation of human cardiomyocytes-derived from induced pluripotent stem cells. J Mol Cell Cardiol. 2014;72:296–304. Epub 2014 Apr 17.
   PubMed Web of Science ®Google Scholar
• Fu JD, Rushing SN, Lieu DK, et al. Distinct roles of microRNA-1 and −499 in ventricular specification and functional maturation of human embryonic stem cell-derived cardiomyocytes. PLoS One. 2011;6:e27417. Epub 2011 Nov 24.
   PubMed Web of Science ®Google Scholar
• Anand SS, Abonyi S, Arbour L, et al. Canadian alliance for healthy hearts and minds: first nations cohort study rationale and design. Prog Community Health Partnersh. 2018;12:55–64.
   PubMedGoogle Scholar
• Zhang B, Montgomery M, Chamberlain MD, et al. Biodegradable scaffold with built-in vasculature for organ-on-a-chip engineering and direct surgical anastomosis. Nat Mater. 2016;15:669–678.
   PubMed Web of Science ®Google Scholar
• Maiullari F, Costantini M, Milan M, et al. A multi-cellular 3D bioprinting approach for vascularized heart tissue engineering based on HUVECs and iPSC-derived cardiomyocytes. Sci Rep. 2018;8:13532.
   PubMed Web of Science ®Google Scholar
• Jha R, Wile B, Wu Q, et al. Molecular beacon-based detection and isolation of working-type cardiomyocytes derived from human pluripotent stem cells. Biomaterials. 2015;50:176–185.
   PubMed Web of Science ®Google Scholar
• Dubois NC, Craft AM, Sharma P, et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol. 2011;29:1011–1018.
   PubMed Web of Science ®Google Scholar
• Tohyama S, Hattori F, Sano M, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell. 2013;12:127–137.
   PubMed Web of Science ®Google Scholar
• Jha R, Wu Q, Singh M, et al. Simulated microgravity and 3D culture enhance induction, viability, proliferation and differentiation of cardiac progenitors from human pluripotent stem cells. Sci Rep. 2016;6:30956.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Jiang J, Han P, et al. Direct differentiation of atrial and ventricular myocytes from human embryonic stem cells by alternating retinoid signals. Cell Res. 2011;21:579–587.
   PubMed Web of Science ®Google Scholar
• Devalla HD, Schwach V, Ford JW, et al. Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology. EMBO Mol Med. 2015;7:394–410. Epub 2015 Feb 24.
   PubMed Web of Science ®Google Scholar
• Lee JH, Protze SI, Laksman Z, et al. Human pluripotent stem cell-derived atrial and ventricular cardiomyocytes develop from distinct mesoderm populations. Cell Stem Cell. 2017;21:179–94.e4. Epub 2017 Aug 5.
   PubMed Web of Science ®Google Scholar
• Jung JJ, Husse B, Rimmbach C, et al. Programming and isolation of highly pure physiologically and pharmacologically functional sinus-nodal bodies from pluripotent stem cells. Stem Cell Reports. 2014;2:592–605. Epub 2014 Jun 18.
   PubMed Web of Science ®Google Scholar
• Ionta V, Liang W, Kim EH, et al. SHOX2 overexpression favors differentiation of embryonic stem cells into cardiac pacemaker cells, improving biological pacing ability. Stem Cell Reports. 2015;4:129–142.
   PubMed Web of Science ®Google Scholar
• Weng Z, Kong CW, Ren L, et al. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev. 2014;23:1704–1716. Epub 2014 Feb 26.
   PubMed Web of Science ®Google Scholar
• Zlochiver S, Munoz V, Vikstrom KL, et al. Electrotonic myofibroblast-to-myocyte coupling increases propensity to reentrant arrhythmias in two-dimensional cardiac monolayers. Biophys J. 2008;95:4469–4480.
   PubMed Web of Science ®Google Scholar
• Miragoli M, Gaudesius G, Rohr S. Electrotonic modulation of cardiac impulse conduction by myofibroblasts. Circ Res. 2006;98:801–810.
   PubMed Web of Science ®Google Scholar
• Vasquez C, Mohandas P, Louie KL, et al. Enhanced fibroblast-myocyte interactions in response to cardiac injury. Circ Res. 2010;107:1011–1020.
   PubMed Web of Science ®Google Scholar
• Rienks M, Papageorgiou AP, Frangogiannis NG, et al. Myocardial extracellular matrix: an ever-changing and diverse entity. Circ Res. 2014;114:872–888.
   PubMed Web of Science ®Google Scholar
• Halper J, Kjaer M. Basic components of connective tissues and extracellular matrix: elastin, fibrillin, fibulins, fibrinogen, fibronectin, laminin, tenascins and thrombospondins. Adv Exp Med Biol. 2014;802:31–47.
   PubMed Web of Science ®Google Scholar
• Chen Z, Xian W, Bellin M, et al. Subtype-specific promoter-driven action potential imaging for precise disease modelling and drug testing in hiPSC-derived cardiomyocytes. Eur Heart J. 2017;38:292–301.
   PubMed Web of Science ®Google Scholar
• Bedut S, Seminatore-Nole C, Lamamy V, et al. High-throughput drug profiling with voltage- and calcium-sensitive fluorescent probes in human iPSC-derived cardiomyocytes. Am J Physiol Heart Circ Physiol. 2016;311:H44–H53.
   PubMed Web of Science ®Google Scholar
• Lee EK, Tran DD, Keung W, et al. Machine learning of human pluripotent stem cell-derived engineered cardiac tissue contractility for automated drug classification. Stem Cell Reports. 2017;9:1560–1572.
   PubMed Web of Science ®Google Scholar
• Park DS, Fishman GI. The cardiac conduction system. Circulation. 2011;123:904–915.
   PubMed Web of Science ®Google Scholar
• Milanesi R, Bucchi A, Baruscotti M. The genetic basis for inherited forms of sinoatrial dysfunction and atrioventricular node dysfunction. J Interv Card Electrophysiol. 2015;43:121–134.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American Heart Association. Circulation. 2017;135:e146–e603.
   PubMed Web of Science ®Google Scholar
• Movahed MR, Hashemzadeh M, Jamal MM. Increased prevalence of third-degree atrioventricular block in patients with type II diabetes mellitus. Chest. 2005;128:2611–2614.
   PubMed Web of Science ®Google Scholar
• Fozzard HA. Afterdepolarizations and triggered activity. Basic Res Cardiol. 1992;2:105–113.
   Google Scholar
• Opie L. Electricity out of control: arrhythmias. Heart Physiology: from cell to circulation. Baltimore: Lippincott Williams & Wilkins; 2004.
   Google Scholar
• Schwartz PJ, Stramba-Badiale M, Crotti L, et al. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761–1767.
   PubMed Web of Science ®Google Scholar
• Tester DJ, Ackerman MJ. Postmortem long QT syndrome genetic testing for sudden unexplained death in the young. J Am Coll Cardiol. 2007;49:240–246.
   PubMed Web of Science ®Google Scholar
• Chiang CE, Roden DM. The long QT syndromes: genetic basis and clinical implications. J Am Coll Cardiol. 2000;36:1–12.
   PubMed Web of Science ®Google Scholar
• Vincent GM, Timothy KW, Leppert M, et al. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med. 1992;327:846–852.
   PubMed Web of Science ®Google Scholar
• Kapplinger JD, Tester DJ, Salisbury BA, et al. Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm. 2009;6:1297–1303.
   PubMed Web of Science ®Google Scholar
• Itzhaki I, Maizels L, Huber I, et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. J Am Coll Cardiol. 2012;60:990–1000.
   PubMed Web of Science ®Google Scholar
• Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471:225–229.
   PubMed Web of Science ®Google Scholar
• Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013. Heart Rhythm. 2013;10:1932–1963.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Maragna R, Faragli A, et al. Gene-specific therapy with mexiletine reduces arrhythmic events in patients with long QT syndrome type 3. J Am Coll Cardiol. 2016;67:1053–1058.
   PubMed Web of Science ®Google Scholar
• Limpitikul WB, Dick IE, Tester DJ, et al. A precision medicine approach to the rescue of function on malignant calmodulinopathic long-QT syndrome. Circ Res. 2017;120:39–48.
   PubMed Web of Science ®Google Scholar
• Sala L, Yu Z, Ward-van Oostwaard D, et al. A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med. 2016;8:1065–1081.
   PubMed Web of Science ®Google Scholar
• Spencer CI, Baba S, Nakamura K, et al. Calcium transients closely reflect prolonged action potentials in iPSC models of inherited cardiac arrhythmia. Stem Cell Reports. 2014;3:269–281.
   PubMed Web of Science ®Google Scholar
• Malan D, Zhang M, Stallmeyer B, et al. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction. Basic Res Cardiol. 2016;111:14.
   PubMed Web of Science ®Google Scholar
• Zhang M, D’Aniello C, Verkerk AO, et al. Recessive cardiac phenotypes in induced pluripotent stem cell models of Jervell and Lange-Nielsen syndrome: disease mechanisms and pharmacological rescue. Proc Natl Acad Sci U S A. 2014;111:E5383–E5392.
   PubMed Web of Science ®Google Scholar
• Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature. 2011;471:230–234. Epub 2011 Feb 11.
   PubMed Web of Science ®Google Scholar
• Rocchetti M, Sala L, Dreizehnter L, et al. Elucidating arrhythmogenic mechanisms of long-QT syndrome CALM1-F142L mutation in patient-specific induced pluripotent stem cell-derived cardiomyocytes. Cardiovasc Res. 2017;113:531–541.
   PubMed Web of Science ®Google Scholar
• Mehta A, Sequiera GL, Ramachandra CJ, et al. Re-trafficking of hERG reverses long QT syndrome 2 phenotype in human iPS-derived cardiomyocytes. Cardiovasc Res. 2014;102:497–506.
   PubMed Web of Science ®Google Scholar
• Mura M, Mehta A, Ramachandra CJ, et al. The KCNH2-IVS9-28A/G mutation causes aberrant isoform expression and hERG trafficking defect in cardiomyocytes derived from patients affected by long QT syndrome type 2. Int J Cardiol. 2017;240:367–371.
   PubMed Web of Science ®Google Scholar
• Hayano M, Makiyama T, Kamakura T, et al. Development of a patient-derived induced pluripotent stem cell model for the investigation of SCN5A-D1275N-related cardiac sodium channelopathy. Circ J. 2017;81:1783–1791.
   PubMed Web of Science ®Google Scholar
• Mehta A, Ramachandra CJA, Singh P, et al. Identification of a targeted and testable antiarrhythmic therapy for long-QT syndrome type 2 using a patient-specific cellular model. Eur Heart J. 2018;39:1446–1455.
   PubMed Web of Science ®Google Scholar
• Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med. 2010;363:1397–1409.
   PubMed Web of Science ®Google Scholar
• Matsa E, Rajamohan D, Dick E, et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32:952–962.
   PubMed Web of Science ®Google Scholar
• Matsa E, Dixon JE, Medway C, et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes. Eur Heart J. 2014;35:1078–1087.
   PubMed Web of Science ®Google Scholar
• Okata S, Yuasa S, Yamane T, et al. The generation of induced pluripotent stem cells from a patient with KCNH2 G603D, without LQT2 disease associated symptom. J Med Dent Sci. 2013;60:17–22.
   PubMedGoogle Scholar
• Egashira T, Yuasa S, Suzuki T, et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res. 2012.
   PubMed Web of Science ®Google Scholar
• Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation. 2013;127:1677–1691.
   PubMed Web of Science ®Google Scholar
• Lahti AL, Kujala VJ, Chapman H, et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012;5:220–230.
   PubMed Web of Science ®Google Scholar
• Terrenoire C, Wang K, Tung KW, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol. 2013;141:61–72.
   PubMed Web of Science ®Google Scholar
• Ma Z, Koo S, Finnegan MA, et al. Three-dimensional filamentous human diseased cardiac tissue model. Biomaterials. 2014;35:1367–1377.
   PubMed Web of Science ®Google Scholar
• Gussak I, Brugada P, Brugada J, et al. Idiopathic short QT interval: a new clinical syndrome? Cardiology. 2000;94:99–102.
   PubMed Web of Science ®Google Scholar
• Mazzanti A, Kanthan A, Monteforte N, et al. Novel insight into the natural history of short QT syndrome. J Am Coll Cardiol. 2014;63:1300–1308.
   PubMed Web of Science ®Google Scholar
• Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol. 2010;3:401–408.
   PubMed Web of Science ®Google Scholar
• Extramiana F, Antzelevitch C. Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation. 2004;110:3661–3666.
   PubMed Web of Science ®Google Scholar
• El-Battrawy I, Lan H, Cyganek L, et al. Modeling short QT syndrome using human-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2018;7:e007394.
   Web of Science ®Google Scholar
• Giustetto C, Schimpf R, Mazzanti A, et al. Long-term follow-up of patients with short QT syndrome. J Am Coll Cardiol. 2011;58:587–595.
   PubMed Web of Science ®Google Scholar
• Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992;20:1391–1396.
   PubMed Web of Science ®Google Scholar
• Antzelevitch C, Brugada P, Borggrefe M, et al. Brugada syndrome: report of the second consensus conference. Heart Rhythm. 2005;2:429–440.
   PubMed Web of Science ®Google Scholar
• Brugada J, Campuzano O, Arbelo E, et al. Present status of brugada syndrome: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:1046–1059.
   PubMed Web of Science ®Google Scholar
• Nabauer M, Beuckelmann DJ, Uberfuhr P, et al. Regional differences in current density and rate-dependent properties of the transient outward current in subepicardial and subendocardial myocytes of human left ventricle. Circulation. 1996;93:168–177.
   PubMed Web of Science ®Google Scholar
• Tukkie R, Sogaard P, Vleugels J, et al. Delay in right ventricular activation contributes to Brugada syndrome. Circulation. 2004;109:1272–1277.
   PubMed Web of Science ®Google Scholar
• Okata S, Yuasa S, Suzuki T, et al. Embryonic type Na+ channel β-subunit, SCN3B masks the disease phenotype of Brugada syndrome. Sci Rep. 2016;6:34198.
   PubMed Web of Science ®Google Scholar
• Liang P, Sallam K, Wu H, et al. Patient-specific and genome-edited induced pluripotent stem cell-derived cardiomyocytes elucidate single-cell phenotype of Brugada Syndrome. J Am Coll Cardiol. 2016;68:2086–2096.
   PubMed Web of Science ®Google Scholar
• Selga E, Sendfeld F, Martinez-Moreno R, et al. Sodium channel current loss of function in induced pluripotent stem cell-derived cardiomyocytes from a Brugada syndrome patient. J Mol Cell Cardiol. 2018;114:10–19. Epub 2017 Oct 13.
   PubMed Web of Science ®Google Scholar
• Gonzalez Corcia MC, de Asmundis C, Chierchia GB, et al. Brugada syndrome in the paediatric population: a comprehensive approach to clinical manifestations, diagnosis, and management. Cardiol Young. 2016;26:1044–1055.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Wilde AA. Catecholaminergic polymorphic ventricular tachycardia: from bench to bedside. Heart. 2013;99:497–504.
   PubMed Web of Science ®Google Scholar
• Hayashi M, Denjoy I, Extramiana F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation. 2009;119:2426–2434.
   PubMed Web of Science ®Google Scholar
• Kozlovski J, Ingles J, Connell V, et al. Delay to diagnosis amongst patients with catecholaminergic polymorphic ventricular tachycardia. Int J Cardiol. 2014;176:1402–1404.
   PubMed Web of Science ®Google Scholar
• Blich M, Marai I, Suleiman M, et al. Electrocardiographic comparison of ventricular premature complexes during exercise test in patients with CPVT and healthy subjects. Pacing Clin Electrophysiol. 2015;38:398–402.
   PubMed Web of Science ®Google Scholar
• Priori SG, Napolitano C, Tiso N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation. 2001;103:196–200.
   PubMed Web of Science ®Google Scholar
• Lahat H, Pras E, Olender T, et al. A missense mutation in a highly conserved region of CASQ2 is associated with autosomal recessive catecholamine-induced polymorphic ventricular tachycardia in Bedouin families from Israel. Am J Hum Genet. 2001;69:1378–1384.
   PubMed Web of Science ®Google Scholar
• Okuda S, Yano M. New data on catecholaminergic polymorphic ventricular tachycardia in Japan: from the bench to the bedside. Circ J. 2013;77:1684–1686.
   PubMed Web of Science ®Google Scholar
• Novak A, Lorber A, Itskovitz-Eldor J, et al. Modeling catecholaminergic polymorphic ventricular tachycardia using induced pluripotent stem cell-derived cardiomyocytes. Rambam Maimonides Med J. 2012;3:e0015. Epub 2013 Aug 3.
   PubMedGoogle Scholar
• Kujala K, Paavola J, Lahti A, et al. Cell model of catecholaminergic polymorphic ventricular tachycardia reveals early and delayed afterdepolarizations. PLoS One. 2012;7:e44660. Epub 2012 Sep 11.
   PubMed Web of Science ®Google Scholar
• Novak A, Barad L, Lorber A, et al. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations. J Cell Mol Med. 2015;19:2006–2018. Epub 2015 Jul 15.
   PubMed Web of Science ®Google Scholar
• Lodola F, Morone D, Denegri M, et al. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2016;7:e2393. Epub 2016 Oct 7.
   PubMed Web of Science ®Google Scholar
• Maizels L, Huber I, Arbel G, et al. Patient-specific drug screening using a human induced pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia type 2. Circ Arrhythm Electrophysiol. 2017;10. Epub 2017 Jun 21.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Zwinderman AH, Wilde AA. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments. Europace. 2012;14:175–183.
   PubMed Web of Science ®Google Scholar
• van der Werf C, Kannankeril PJ, Sacher F, et al. Flecainide therapy reduces exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. J Am Coll Cardiol. 2011;57:2244–2254.
   PubMed Web of Science ®Google Scholar
• Watanabe H, van der Werf C, Roses-Noguer F, et al. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10:542–547.
   PubMed Web of Science ®Google Scholar
• Khoury A, Marai I, Suleiman M, et al. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia. Heart Rhythm. 2013;10:1671–1675.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Chopra N, Laver D, et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med. 2009;15:380–383.
   PubMed Web of Science ®Google Scholar
• Bannister ML, Thomas NL, Sikkel MB, et al. The mechanism of flecainide action in CPVT does not involve a direct effect on RyR2. Circ Res. 2015;116:1324–1335.
   PubMed Web of Science ®Google Scholar
• Preininger MK, Jha R, Maxwell JT, et al. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses. Dis Model Mech. 2016;9:927–939. Epub 2016 Aug 5.
   PubMed Web of Science ®Google Scholar
• Di Pasquale E, Lodola F, Miragoli M, et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia. Cell Death Dis. 2013;4:e843. Epub 2013 Oct 12.
   PubMed Web of Science ®Google Scholar
• Fatima A, Xu G, Shao K, et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol Biochem. 2011;28:579–592. Epub 2011 Dec 20.
   PubMed Web of Science ®Google Scholar
• Jung CB, Moretti A, Mederos Y Schnitzler M, et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol Med. 2012;4:180–191. Epub 2011 Dec 17.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Makiyama T, Yoshida Y, et al. Patient-specific human induced pluripotent stem cell model assessed with electrical pacing validates S107 as a potential therapeutic agent for catecholaminergic polymorphic ventricular tachycardia. PLoS One. 2016;11:e0164795. Epub 2016 Oct 21.
   PubMed Web of Science ®Google Scholar
• Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol. 2008;52:2175–2187.
   PubMed Web of Science ®Google Scholar
• Thiene G, Nava A, Corrado D, et al. Right ventricular cardiomyopathy and sudden death in young people. N Engl J Med. 1988;318:129–133.
   PubMed Web of Science ®Google Scholar
• Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation. 2006;113:1634–1637.
   PubMed Web of Science ®Google Scholar
• Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study group on arrhythmogenic right ventricular dysplasia/cardiomyopathy of the working groups on myocardial and pericardial disease and arrhythmias of the European Society of Cardiology and of the scientific council on cardiomyopathies of the World Heart Federation. Circulation. 2000;101:E101–E106.
   PubMed Web of Science ®Google Scholar
• Basso C, Thiene G, Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation. 1996;94:983–991.
   PubMed Web of Science ®Google Scholar
• Nava A, Thiene G, Canciani B, et al. Clinical profile of concealed form of arrhythmogenic right ventricular cardiomyopathy presenting with apparently idiopathic ventricular arrhythmias. Int J Cardiol. 1992;35:195–206. discussion 7–9.
   PubMed Web of Science ®Google Scholar
• Daliento L, Turrini P, Nava A, et al. Arrhythmogenic right ventricular cardiomyopathy in young versus adult patients: similarities and differences. J Am Coll Cardiol. 1995;25:655–664.
   PubMed Web of Science ®Google Scholar
• Pinamonti B, Sinagra G, Salvi A, et al. Left ventricular involvement in right ventricular dysplasia. Am Heart J. 1992;123:711–724.
   PubMed Web of Science ®Google Scholar
• Christensen AH, Benn M, Bundgaard H, et al. Wide spectrum of desmosomal mutations in Danish patients with arrhythmogenic right ventricular cardiomyopathy. J Med Genet. 2010;47:736–744.
   PubMed Web of Science ®Google Scholar
• Kowalczyk AP, Green KJ. Structure, function, and regulation of desmosomes. Prog Mol Biol Transl Sci. 2013;116:95–118.
   PubMed Web of Science ®Google Scholar
• Gandjbakhch E, Redheuil A, Pousset F, et al. Clinical diagnosis, imaging, and genetics of arrhythmogenic right ventricular cardiomyopathy/dysplasia: JACC state-of-the-art review. J Am Coll Cardiol. 2018;72:784–804.
   PubMed Web of Science ®Google Scholar
• Caspi O, Huber I, Gepstein A, et al. Modeling of arrhythmogenic right ventricular cardiomyopathy with human induced pluripotent stem cells. Circ Cardiovasc Genet. 2013;6:557–568. Epub 2013 Nov 10.
   PubMed Web of Science ®Google Scholar
• Ma D, Wei H, Lu J, et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. Eur Heart J. 2013;34:1122–1133. Epub 2012 Jul 17.
   PubMed Web of Science ®Google Scholar
• Kim C, Wong J, Wen J, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature. 2013;494:105–110. Epub 2013 Jan 29.
   PubMed Web of Science ®Google Scholar
• Lal H, Ahmad F, Woodgett J, et al. The GSK-3 family as therapeutic target for myocardial diseases. Circ Res. 2015;116:138–149.
   PubMed Web of Science ®Google Scholar
• Chelko SP, Asimaki A, Andersen P, et al. Central role for GSK3beta in the pathogenesis of arrhythmogenic cardiomyopathy. JCI Insight. 2016;1.
   PubMed Web of Science ®Google Scholar
• Dorn T, Kornherr J, Parrotta EI, et al. Interplay of cell–cell contacts and RhoA/MRTF‐A signaling regulates cardiomyocyte identity. Embo J. 2018;37:e98133.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA study. Coronary artery risk development in (young) adults. Circulation. 1995;92:785–789.
   PubMed Web of Science ®Google Scholar
• Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2008;29:270–276.
   PubMed Web of Science ®Google Scholar
• Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res. 2017;121:749–770.
   PubMed Web of Science ®Google Scholar
• Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation. 2000;102:858–864.
   PubMed Web of Science ®Google Scholar
• O’Mahony C, Jichi F, Pavlou M, et al. Hypertrophic cardiomyopathy outcomes I. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35:2010–2020.
   PubMed Web of Science ®Google Scholar
• Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation. 2003;107:2227–2232.
   PubMed Web of Science ®Google Scholar
• Tsoutsman T, Lam L, Semsarian C. Genes, calcium and modifying factors in hypertrophic cardiomyopathy. Clin Exp Pharmacol Physiol. 2006;33:139–145.
   PubMed Web of Science ®Google Scholar
• Maron BJ, McKenna WJ, Danielson GK, et al. Task force on clinical expert consensus documents. American College of C, Committee for Practice Guidelines. European Society of C. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687–1713.
   PubMed Web of Science ®Google Scholar
• Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J. 1958;20:1–8.
   PubMedGoogle Scholar
• Maron BJ, Wolfson JK, Epstein SE, et al. Intramural (“small vessel”) coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol. 1986;8:545–557.
   PubMed Web of Science ®Google Scholar
• Prondzynski M, Kramer E, Laufer SD, et al. Evaluation of MYBPC3 trans-splicing and gene replacement as therapeutic options in human iPSC-derived cardiomyocytes. Mol Ther Nucleic Acids. 2017;7:475–486. Epub 2017 Jun 19.
   PubMedGoogle Scholar
• Han L, Li Y, Tchao J, et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells. Cardiovasc Res. 2014;104:258–269. Epub 2014 Sep 12.
   PubMed Web of Science ®Google Scholar
• Dambrot C, Braam SR, Tertoolen LG, et al. Serum supplemented culture medium masks hypertrophic phenotypes in human pluripotent stem cell derived cardiomyocytes. J Cell Mol Med. 2014;18:1509–1518. Epub 2014 Jul 2.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Yuasa S, Mearini G, et al. Endothelin-1 induces myofibrillar disarray and contractile vector variability in hypertrophic cardiomyopathy-induced pluripotent stem cell-derived cardiomyocytes. J Am Heart Assoc. 2014;3:e001263. Epub 2014 Nov 13.
   PubMed Web of Science ®Google Scholar
• Birket MJ, Ribeiro MC, Kosmidis G, et al. Contractile defect caused by mutation in MYBPC3 revealed under conditions optimized for human PSC-cardiomyocyte function. Cell Rep. 2015;13:733–745.
   PubMed Web of Science ®Google Scholar
• Authors/Task Force m, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35:2733–2779.
   PubMed Web of Science ®Google Scholar
• Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell. 2013;12:101–113. Epub 2013 Jan 8.
   PubMed Web of Science ®Google Scholar
• Jouni M, Si-Tayeb K, Es-Salah-Lamoureux Z, et al. Toward personalized medicine: using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of type 2 long QT syndrome. J Am Heart Assoc. 2015;4:e002159.
   PubMed Web of Science ®Google Scholar
• Ma D, Wei H, Zhao Y, et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. Int J Cardiol. 2013;168:5277–5286.
   PubMed Web of Science ®Google Scholar
• Carvajal-Vergara X, Sevilla A, D’Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature. 2010;465:808–812. Epub 2010 Jun 11.
   PubMed Web of Science ®Google Scholar
• Ma D, Wei H, Lu J, et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther. 2015;6:39.
   PubMed Web of Science ®Google Scholar
• Bellin M, Casini S, Davis RP, et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. Embo J. 2013;32:3161–3175.
   PubMed Web of Science ®Google Scholar
• Monteiro Da Rocha A, Guerrero-Serna G, Helms A, et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. J Mol Cell Cardiol. 2016;99:197–206. Epub 2016 Sep 14.
   PubMed Web of Science ®Google Scholar
• Fatima A, Kaifeng S, Dittmann S, et al. The disease-specific phenotype in cardiomyocytes derived from induced pluripotent stem cells of two long QT syndrome type 3 patients. PLoS One. 2013;8:e83005.
   PubMed Web of Science ®Google Scholar
• Ojala M, Prajapati C, Polonen RP, et al. Mutation-specific phenotypes in hiPSC-derived cardiomyocytes carrying either myosin-binding protein C or alpha-tropomyosin mutation for hypertrophic cardiomyopathy. Stem Cells Int. 2016;2016:1684792. Epub 2016 Apr 9.
   PubMedGoogle Scholar
• Strauss DG, Blinova K. Clinical trials in a dish. Trends Pharmacol Sci. 2017;38:4–7.
   PubMed Web of Science ®Google Scholar
• Colatsky T, Fermini B, Gintant G, et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - update on progress. J Pharmacol Toxicol Methods. 2016;81:15–20.
   PubMed Web of Science ®Google Scholar
• Ma N, Zhang J, Itzhaki I, et al. Determining the pathogenicity of a genomic variant of uncertain significance using CRISPR/Cas9 and human-induced pluripotent stem cells. Circulation. 2018;138(23):2666–2681.
   Web of Science ®Google Scholar
• Garg P, Oikonomopoulos A, Chen H, et al. Genome editing of induced pluripotent stem cells to decipher cardiac channelopathy variant. J Am Coll Cardiol. 2018;72:62–75.
   PubMed Web of Science ®Google Scholar